AEON Biopharma, Inc., a clinical-stage biopharmaceutical entity specializing in the discovery of therapeutic neurotoxins and medications for neurological conditions, has seen a significant shift in its ownership structure. According to a Schedule 13G filing submitted on November 13, 2026, Nantahala Capital Management, LLC, alongside two associated individuals, has established a substantial position in the company.

The filing reveals that the reporting persons collectively hold just under ten percent of AEON Biopharma’s common stock. Specifically, each beneficiary’s ownership is cited at 9.99%. While this concentration of equity is noteworthy, the documentation clarifies that these holdings are maintained in the ordinary course of business and are not intended to exert control over the issuer. The filing serves as a routine update regarding beneficial ownership and does not signal immediate changes to the company’s corporate structure or operational direction.

Despite the lack of disclosed operational shifts, the company’s market position remains a point of intense observation. Traded on the NYSE American, AEON Biopharma currently maintains a market capitalization of approximately $10.94 million. The stock has experienced significant volatility over the past year; after reaching a 52-week high of $1.45 in February 2026, the price has retreated significantly, trading at $0.153 as of November 12, 2026, near its 52-week low of $0.127 recorded in early November.

As the company continues its clinical-stage development from its base in Irvine, United States, the entry of institutional interest via Nantahala Capital Management provides a layer of scrutiny to its valuation. Investors will be watching closely to see if this accumulation of shares precedes any fundamental breakthroughs in the company’s neurological therapeutic pipeline.